Next Article in Journal
Molecular Classification as a Predictor of Nodal Involvement and Survival Outcomes in Presumed Early-Stage Endometrial Cancer
Previous Article in Journal
Circulating Biomarkers in Localized Anal Squamous Cell Carcinoma Across Treatment Timepoints: A Systematic Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers 2021, 13, 6256

by
Rubén Rodríguez-Bautista
1,2,
Claudia H. Caro-Sánchez
3,
Paula Cabrera-Galeana
4,
Gerardo J. Alanis-Funes
5,
Everardo Gutierrez-Millán
6,
Santiago Ávila-Ríos
7,
Margarita Matías-Florentino
7,
Gustavo Reyes-Terán
7,
José Díaz-Chávez
8,
Cynthia Villarreal-Garza
4,9,
Norma Y. Hernández-Pedro
1,
Alette Ortega-Gómez
10,
Luis Lara-Mejía
11,
Claudia Rangel-Escareño
12,13,* and
Oscar Arrieta
1,11,*
1
Laboratorio de Medicina Personalizada de la Unidad de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico
2
Programa de Doctorado en Ciencias Biomédicas, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
3
Departmento de Patología, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico
4
Departamento de Oncología Médica-Tumores Mamarios, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico
5
Bio Assisted Sequencing Environment National Sequencing Laboratory (Tec-BASE), School of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico
6
Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca 62100, Mexico
7
Centro de Investigación de Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City 14080, Mexico
8
Unidad de Investigación Biomédica en Cáncer, INCan-Instituto de Investigaciones Biomédicas, UNAM, Mexico City 14080, Mexico
9
Centro de Cáncer de Mama, Hospital Zambrano Hellion, Tecnologico de Monterrey, Monterrey 66278, Mexico
10
Laboratorio de Medicina Traslacional, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico
11
Thoracic Oncology Unit, Department of Thoracic Oncology, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico
12
School of Engineering and Sciences, Tecnologico de Monterrey, Epigmenio González 500, San Pablo, Santiago de Querétaro 76130, Mexico
13
Computational Genomics and Integrative Biology, National Institute of Genomic Medicine (INMEGEN), Periférico Sur 4809 Arenal Tepepan, Mexico City 14610, Mexico
*
Authors to whom correspondence should be addressed.
Cancers 2026, 18(10), 1627; https://doi.org/10.3390/cancers18101627
Submission received: 28 January 2026 / Accepted: 3 March 2026 / Published: 18 May 2026
(This article belongs to the Section Molecular Cancer Biology)
Errors in Sections 2.4, 2.7 and 3.2
In the original publication [1], several minor textual and tabular transcription issues and an ambiguous phrasing were identified in Sections 2.4, 2.7, and 3.2. The corrected text appears below.
Error in Section 2.4: Classification of TNBC Patients in IM and Non-IM Subtypes
The sentence “All 68 samples were inserted into the algorithm, which classified 55 samples into one of the aforementioned subtypes; in total, 11 samples were labeled as unclassified.” has been corrected to “All 68 samples were inserted into the algorithm, which classified 55 samples into one of the aforementioned subtypes; in total, 13 samples were labeled as unclassified.”
Error in Section 2.7: Statistical Analyses
The software attribution “R statistical software version 4.1.1 (GPL Technologies, Burbank, CA, USA)” has been corrected to “R statistical software version 4.1.1 (R Core Team, Vienna, Austria)”.
Error in Section 3.2: Treatment Management of TNBC Patients
The sentence “Out of the cohort of 57 patients with clinical stage III disease, 70.2% did not respond to treatment.” has been corrected to “Out of the cohort of 57 patients with clinical stage III disease, 40 (70.2%) had at least one high-risk pathological feature (positive axillary lymph nodes, histologic grade 3, Ki-67 index > 20% or lymphovascular invasion)”.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Rodríguez-Bautista, R.; Caro-Sánchez, C.H.; Cabrera-Galeana, P.; Alanis-Funes, G.J.; Gutierrez-Millán, E.; Ávila-Ríos, S.; Matías-Florentino, M.; Reyes-Terán, G.; Díaz-Chávez, J.; Villarreal-Garza, C.; et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers 2021, 13, 6256. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rodríguez-Bautista, R.; Caro-Sánchez, C.H.; Cabrera-Galeana, P.; Alanis-Funes, G.J.; Gutierrez-Millán, E.; Ávila-Ríos, S.; Matías-Florentino, M.; Reyes-Terán, G.; Díaz-Chávez, J.; Villarreal-Garza, C.; et al. Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers 2021, 13, 6256. Cancers 2026, 18, 1627. https://doi.org/10.3390/cancers18101627

AMA Style

Rodríguez-Bautista R, Caro-Sánchez CH, Cabrera-Galeana P, Alanis-Funes GJ, Gutierrez-Millán E, Ávila-Ríos S, Matías-Florentino M, Reyes-Terán G, Díaz-Chávez J, Villarreal-Garza C, et al. Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers 2021, 13, 6256. Cancers. 2026; 18(10):1627. https://doi.org/10.3390/cancers18101627

Chicago/Turabian Style

Rodríguez-Bautista, Rubén, Claudia H. Caro-Sánchez, Paula Cabrera-Galeana, Gerardo J. Alanis-Funes, Everardo Gutierrez-Millán, Santiago Ávila-Ríos, Margarita Matías-Florentino, Gustavo Reyes-Terán, José Díaz-Chávez, Cynthia Villarreal-Garza, and et al. 2026. "Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers 2021, 13, 6256" Cancers 18, no. 10: 1627. https://doi.org/10.3390/cancers18101627

APA Style

Rodríguez-Bautista, R., Caro-Sánchez, C. H., Cabrera-Galeana, P., Alanis-Funes, G. J., Gutierrez-Millán, E., Ávila-Ríos, S., Matías-Florentino, M., Reyes-Terán, G., Díaz-Chávez, J., Villarreal-Garza, C., Hernández-Pedro, N. Y., Ortega-Gómez, A., Lara-Mejía, L., Rangel-Escareño, C., & Arrieta, O. (2026). Correction: Rodríguez-Bautista et al. Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers 2021, 13, 6256. Cancers, 18(10), 1627. https://doi.org/10.3390/cancers18101627

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop